About the Journal

ABOUT JOURNAL PHARMACTIVE

Journal Pharmactive is a journal managed and published by the Institute for Research and Community Service (LPPM) Institut Teknologi dan Kesehatan Bintang Persada, with e-ISSN 2829-3444. Journal Pharmactive was first published in April 2022 and has a publishing period twice in a year, namely in April and September.

All articles in Journal Pharmactive will be processed by the editor through the Online Journal System (OJS), and the author can monitor the entire process in the member area. Articles published in Journal Pharmactive, both in hardcopy and soft copy, are available as open access for educational, research and library purposes, and beyond that purpose, the Journal Pharmactive editorial board is not responsible for copyright infringement.

FOCUS AND SCOPE

  1. Clinical and Community Pharmacy
  2. Pharmaceutical Analysis
  3. Herbal Medicine
  4. Pharmaceutical Technology
  5. Management of Pharmacy

 

HISTORY JOURNAL

Initially LPPM Institut Teknologi dan Kesehatan Bintang Persada published a journal that aimed to accommodate campus internal lecturers at Institut Teknologi dan Kesehatan Bintang Persada in publishing scientific papers. Because the lecturers who want to carry out publications come from various fields of science, such as Clinical andCommunity Pharmacy, Pharmaceutical Analysis, Herbal Medicine, Pharmaceutical Techology, Management of Pharmacy, etc. the published journal seems not to have a clear focus area (accepting all types of articles). In addition, efforts to improve journal management by LPPM, as well as accreditation demands for scientific periodicals / journals determined by related parties.

Journal Pharmactive is one of the journals managed and published by LPPM Institut Teknologi dan Kesehatan Bintang Persada to facilitate the publication of scientific articles of lecturers in the fields of pharmacy. 

With the presence of this journal, it is expected that journal management in LPPM Institut Teknologi dan Kesehatan Bintang Persada will be more focused on pharmacy cluster and meet applicable standards. Hopefully the publication of this journal can provide new information and inspiration as well as add insights and examples of the application of weighted information and science to stakeholders.

 

OPEN ACCESS POLICY

The author's copyright in the Journal Pharmactive, assigns that the publication of published articles is owned by the editorial board with the author's approval, but the rights are still with the author. The legal rules for accessing digital electronic articles are under license   Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) , which means that the Journal Pharmactive has the right to store, modify, manage databases, maintain and publish articles without the author's permission, but the author as the copyright holder is still written as it is. Articles published in Journal Pharmactives, both in hard and soft copy forms are available as open access, for educational, research and library purposes, and beyond that purpose, the editorial board of the Language and Language Journal is not responsible for illegal copyright infringement. This journal also applies LOCKSS and CLOKSS archiving.

 

COPYRIGHT NOTICE

Author(s) who publish article in Journal Pharmactive, agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under license   Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

 

PEER REVIEW PROCESS

The article that has been sent to Journal Pharmactive will be through two review process namely pre-review and review. Pre-review process of the article is done by managing director that include:

  1. Focus and Scope: The article being sent should in accordance with the scope of Journal Pharmactive, focus and scope can be seen here. The article outside the scope of Journal Pharmactive will be rejected.
  2. Plagiarism Check: Plagiarism check and article similarity are done by using google schoolar and itenthicate with maximum score 15%. Article that has similarity check above 15% will be returned to the writer for revision.
  3. References: references used in the article are minimum 10 references that consist of 80% primary sources and 20% secondary sources. References use IEEE style and made by using references managing software like Mendeley.
  4. Template: the submitted article should in accordance with the template in Journal Pharmactive which can be seen and downloaded here.

If from the four components, there is something not in accordance, then the article will be returned to the writer to be revised. Writer is given time for seven days to revise the article and send it back.

When the four components in the review process are fulfilled, then the article will be continued to be reviewed by the reviewer through editor. The substances review process is done by three reviewer in Double Blind Peer Review. Reviewer can give recommendation such as:

  1. Accept Submission: article is accepted to be published without having revision in substances.
  2. Revision Required: the article with minor revision, article is sent to the writer to be revised (when the writer has sent the revision, article can be accepted to be published)
  3. Resubmit for Review: the article with major revision. After revision is done by the writer, article is resubmitted to the reviewer to be reviewed again ( maximum three times resubmit), If the article is not quite right in substance after the fourth review, then reviewer is allowed to give recommendation as Decline Submission.
  4. Resubmit Elsewhere : in substance, article is considered as less suitable and suggested to be submitted into other journal
  5. Decline Submission: article is rejected by the reviewer to be reviewed with two reasons, (1) reviewer rejects because of a reason (not related to articles substances), then the article is sent to another reviewer. (2) rejected article in substance is considered less suitable to be published in journal.

 

ARTICLE PROCESSING TIME ON JOURNAL PHARMACTIVE

Pre-review process takes time about 3-7 days

Writer has 1 week to revise the article in pre-review stage. Writer who has not revised the article at that time and without giving any statement, then the managing director has done meaningless work, then the article will be rejected.

Review process by the reviewer is done about 2 weeks every round. The numbers of round in review process depends on the reviewer recommendations.

Writer is given one week to revise the article from reviewer, and if the writer does not send the revision at the specified time without any statement, then editor and reviewer has done meaningless work, then the article is rejected.

The duration of the article starts from the submitting until production stage in detail can be seen in the image below.

LOA (LETTER OF ACCEPTANCE)

LOA on Journal Pharmactive consists of 2 types, those are LOA that will be sent through the writers email automatically by OJS when the article has been accepted to be published.

Second LOA is manual LOA that will be attached on the discussion section on OJS when the article has been accepted to be published.

LOA will only be given to the writer when the article has entered production stage.

 

ARTICLE REJECTION

Manuscript rejection or manuscript cancellation on Journal Pharmactive consists of two types, namely rejection or withdrawal without fine, and rejection or withdrawal with fine. Withdrawal without fine happens because of three things, those are:

  1. Do not in accordance with the focus and scope.
  2. Writer do not revise the article both in pre-review and review stage along the specified tine without any reason.
  3. Article rejection by recommendation of the reviewer related to substances/content of the article

Rejection or withdrawal with fine happens because of two things, those are:

  1. Writer that takes his writing with any reasons when the article has been proceed (enter the pre-review stage by the managing director).
  2. There is duplication in publication, where the writer do submitting article in several journal and one of them is Journal Pharmactive, or the article has been published in another journal and re-submit on Journal Pharmactive.

 

PUBLICATION ETHICS AND MALPRACTICE STATEMENT

These guidelines are fully suitable with the COPE Principles of Transparency and Best Practice Guidelines and the COPE Code of Conduct. For more details can be seen in the following link: https://publicationethics.org

Section A: Publication and authorship 

  1. All submitted papers are subject to strict peer-review process by at least two international reviewers that are experts in the area of the particular paper.
  2. Review process are blind peer review.
  3. The factors that are taken into account in review are relevance, soundness, significance, originality, readability and language.
  4. The possible decisions include acceptance, acceptance with revisions, or rejection.
  5. If authors are encouraged to revise and resubmit a submission, there is no guarantee that the revised submission will be accepted.
  6. Rejected articles will not be re-reviewed.
  7. The paper acceptance is constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism.
  8. No research can be included in more than one publication. 

Section B: Authors responsibilities

  1. Authors must certify that their manuscripts are their original work.
  2. Authors must certify that the manuscript has not previously been published elsewhere.
  3. Authors must certify that the manuscript is not currently being considered for publication elsewhere. 
  4. Authors must participate in the peer review process. 
  5. Authors are obliged to provide retractions or corrections of mistakes.
  6. All Authors mentioned in the paper must have significantly contributed to the research.
  7. Authors must state that all data in the paper are real and authentic.
  8. Authors must notify the Editors of any conflicts of interest.
  9. Authors must identify all sources used in the creation of their manuscript.
  10. Authors must report any errors they discover in their published paper to the Editors. 

Section C: Reviewers responsibilities

  1. Reviewers should keep all information regarding papers confidential and treat them as privileged information. 
  2. Reviews should be conducted objectively, with no personal criticism of the author
  3. Reviewers should express their views clearly with supporting arguments
  4. Reviewers should identify relevant published work that has not been cited by the authors.
  5. Reviewers should also call to the Editor in Chiefs attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
  6. Reviewers should not review manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers. 

Section D: Editors responsibilities

  1. Editors have complete responsibility and authority to reject/accept an article.
  2. Editors are responsible for the contents and overall quality of the publication.
  3. Editors should always consider the needs of the authors and the readers when attempting to improve the publication.
  4. Editors should guarantee the quality of the papers and the integrity of the academic record.
  5. Editors should publish errata pages or make corrections when needed.
  6. Editors should have a clear picture of a researchs funding sources.
  7. Editors should base their decisions solely one the papers importance, originality, clarity and relevance to publications scope.
  8. Editors should not reverse their decisions nor overturn the ones of previous editors without serious reason. 
  9. Editors should preserve the anonymity of reviewers. 
  10. Editors should ensure that all research material they publish conforms to internationally accepted ethical guidelines.
  11. Editors should only accept a paper when reasonably certain.
  12. Editors should act if they suspect misconduct, whether a paper is published or unpublished, and make all reasonable attempts to persist in obtaining a resolution to the problem.
  13. Editors should not reject papers based on suspicions, they should have proof of misconduct.
  14. Editors should not allow any conflicts of interest between staff, authors, reviewers and board members.